Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | CCR8 | P51685 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734268 | 0.84 | KDM4E (0.44) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL435144 | 0.84 | KDM4E (0.44) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL27936240 | 0.81 | KDM4E (0.41) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL5577241 | 0.81 | KDM4E (0.41) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL6502675 | 0.81 | KDM4E (0.41) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL10416676 | 0.81 | NOS3 (0.43) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL11121873 | 0.81 | NOS3 (0.43) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL19435589 | 0.81 | KDM4E (0.41) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL16261706 | 0.80 | ALDH1A1 (0.37) | KDM4ELMNAP4HTMCCR1CCR5 | |
| SCHEMBL29244877 | 0.79 | NOS3 (0.41) | KDM4ELMNAP4HTMCCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | claimed |
| CN-111620849-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2023-11-14 | — | — | CN | claimed |
| CN-111620849-A | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-09-04 | — | — | CN | claimed |
| CN-107108553-B | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-04-28 | — | — | CN | claimed |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| CN-111295444-B | Polynomial coding for oligonucleotide-directed combinatorial chemistry | 哈斯达克科学公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111620849-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-115820806-A | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-109312492-B | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | SAINT LOUIS UNIVERSITY (US) | 2022-08-25 | — | — | US | disclosed |
| CN-110325491-B | Method and composition for synthesizing coding library | 成都先导药物开发股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| WO-1995003316-A3 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-03-30 | — | — | WO | disclosed |
| WO-1995003316-A2 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003316-A2 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-02-02 | — | — | WO | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | BCAT2, BCAT1, ABAT | KDM4E 1468/4885LMNA 3561/4885P4HTM 1728/4885 |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | KDM4E 3664/4885LMNA 1975/4885P4HTM 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.